Concerning PNPLA3, it has been recently suggested that the I148M variant may be a gain-of-function mutation that promotes hepatic steatosis by accumulating lipid droplets and inhibiting other lipases in an ABHD5-dependent manner [51]. This evidence concerns the gene PNPLA3 and fatty liver disease.